Doxepin for radiation therapy-induced mucositis pain in the treatment of oral cancers

Ritujith Jayakrishnan, Kenneth Chang, Gamze Ugurluer, Robert C. Miller, Terence T. Sio

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Radiotherapy (RT), an integral part of the oncologic treatment for patients with head and neck cancer, can cause adverse side effects such as oral mucositis (OM). Pain from OM can impact a patient's quality of life and interrupt RT treatment schedules, which decreases the probability for achieving cancer cure. Conventionally, RT-induced OM pain is treated with analgesics and/or mouthwash rinses. Doxepin, a traditional tricyclic antidepressant with analgesic and anesthetic properties when applied topically to the mucosa, has been shown to lower OM pain in multiple single-arm trials (Epstein et al.) and more recently, in a placebo-controlled crossover study (Leenstra and Miller et al.). Currently, a placebo-controlled study (Sio and Miller et al.) using doxepin for esophagitis pain caused by RT to the thorax is underway. Doxepin will also be further compared with magic mouthwash and a placebo solution in a three-arm trial (Miller and Sio et al.) with head and neck cancer patients with OM pain caused by RT. Doxepin may represent a new standard for treating RT-induced OM pain in the future.

Original languageEnglish (US)
Pages (from-to)35-37
Number of pages3
JournalOncology Reviews
Volume9
Issue number1
DOIs
StatePublished - 2015

Fingerprint

Doxepin
Stomatitis
Mucositis
Mouth Neoplasms
Radiotherapy
Pain
Mouthwashes
Placebos
Head and Neck Neoplasms
Analgesics
Therapeutics
Magic
Esophagitis
Tricyclic Antidepressive Agents
Cross-Over Studies
Anesthetics
Appointments and Schedules
Mucous Membrane
Arm
Thorax

Keywords

  • Doxepin
  • Head and neck cancer
  • Oral mucositis
  • Radiation therapy
  • Symptom control

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Jayakrishnan, R., Chang, K., Ugurluer, G., Miller, R. C., & Sio, T. T. (2015). Doxepin for radiation therapy-induced mucositis pain in the treatment of oral cancers. Oncology Reviews, 9(1), 35-37. https://doi.org/10.4081/oncol.2015.290

Doxepin for radiation therapy-induced mucositis pain in the treatment of oral cancers. / Jayakrishnan, Ritujith; Chang, Kenneth; Ugurluer, Gamze; Miller, Robert C.; Sio, Terence T.

In: Oncology Reviews, Vol. 9, No. 1, 2015, p. 35-37.

Research output: Contribution to journalReview article

Jayakrishnan, R, Chang, K, Ugurluer, G, Miller, RC & Sio, TT 2015, 'Doxepin for radiation therapy-induced mucositis pain in the treatment of oral cancers', Oncology Reviews, vol. 9, no. 1, pp. 35-37. https://doi.org/10.4081/oncol.2015.290
Jayakrishnan, Ritujith ; Chang, Kenneth ; Ugurluer, Gamze ; Miller, Robert C. ; Sio, Terence T. / Doxepin for radiation therapy-induced mucositis pain in the treatment of oral cancers. In: Oncology Reviews. 2015 ; Vol. 9, No. 1. pp. 35-37.
@article{a15670295bc14e0da34445124808d659,
title = "Doxepin for radiation therapy-induced mucositis pain in the treatment of oral cancers",
abstract = "Radiotherapy (RT), an integral part of the oncologic treatment for patients with head and neck cancer, can cause adverse side effects such as oral mucositis (OM). Pain from OM can impact a patient's quality of life and interrupt RT treatment schedules, which decreases the probability for achieving cancer cure. Conventionally, RT-induced OM pain is treated with analgesics and/or mouthwash rinses. Doxepin, a traditional tricyclic antidepressant with analgesic and anesthetic properties when applied topically to the mucosa, has been shown to lower OM pain in multiple single-arm trials (Epstein et al.) and more recently, in a placebo-controlled crossover study (Leenstra and Miller et al.). Currently, a placebo-controlled study (Sio and Miller et al.) using doxepin for esophagitis pain caused by RT to the thorax is underway. Doxepin will also be further compared with magic mouthwash and a placebo solution in a three-arm trial (Miller and Sio et al.) with head and neck cancer patients with OM pain caused by RT. Doxepin may represent a new standard for treating RT-induced OM pain in the future.",
keywords = "Doxepin, Head and neck cancer, Oral mucositis, Radiation therapy, Symptom control",
author = "Ritujith Jayakrishnan and Kenneth Chang and Gamze Ugurluer and Miller, {Robert C.} and Sio, {Terence T.}",
year = "2015",
doi = "10.4081/oncol.2015.290",
language = "English (US)",
volume = "9",
pages = "35--37",
journal = "Oncology Reviews",
issn = "1970-5557",
publisher = "PagePress",
number = "1",

}

TY - JOUR

T1 - Doxepin for radiation therapy-induced mucositis pain in the treatment of oral cancers

AU - Jayakrishnan, Ritujith

AU - Chang, Kenneth

AU - Ugurluer, Gamze

AU - Miller, Robert C.

AU - Sio, Terence T.

PY - 2015

Y1 - 2015

N2 - Radiotherapy (RT), an integral part of the oncologic treatment for patients with head and neck cancer, can cause adverse side effects such as oral mucositis (OM). Pain from OM can impact a patient's quality of life and interrupt RT treatment schedules, which decreases the probability for achieving cancer cure. Conventionally, RT-induced OM pain is treated with analgesics and/or mouthwash rinses. Doxepin, a traditional tricyclic antidepressant with analgesic and anesthetic properties when applied topically to the mucosa, has been shown to lower OM pain in multiple single-arm trials (Epstein et al.) and more recently, in a placebo-controlled crossover study (Leenstra and Miller et al.). Currently, a placebo-controlled study (Sio and Miller et al.) using doxepin for esophagitis pain caused by RT to the thorax is underway. Doxepin will also be further compared with magic mouthwash and a placebo solution in a three-arm trial (Miller and Sio et al.) with head and neck cancer patients with OM pain caused by RT. Doxepin may represent a new standard for treating RT-induced OM pain in the future.

AB - Radiotherapy (RT), an integral part of the oncologic treatment for patients with head and neck cancer, can cause adverse side effects such as oral mucositis (OM). Pain from OM can impact a patient's quality of life and interrupt RT treatment schedules, which decreases the probability for achieving cancer cure. Conventionally, RT-induced OM pain is treated with analgesics and/or mouthwash rinses. Doxepin, a traditional tricyclic antidepressant with analgesic and anesthetic properties when applied topically to the mucosa, has been shown to lower OM pain in multiple single-arm trials (Epstein et al.) and more recently, in a placebo-controlled crossover study (Leenstra and Miller et al.). Currently, a placebo-controlled study (Sio and Miller et al.) using doxepin for esophagitis pain caused by RT to the thorax is underway. Doxepin will also be further compared with magic mouthwash and a placebo solution in a three-arm trial (Miller and Sio et al.) with head and neck cancer patients with OM pain caused by RT. Doxepin may represent a new standard for treating RT-induced OM pain in the future.

KW - Doxepin

KW - Head and neck cancer

KW - Oral mucositis

KW - Radiation therapy

KW - Symptom control

UR - http://www.scopus.com/inward/record.url?scp=84981276170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981276170&partnerID=8YFLogxK

U2 - 10.4081/oncol.2015.290

DO - 10.4081/oncol.2015.290

M3 - Review article

VL - 9

SP - 35

EP - 37

JO - Oncology Reviews

JF - Oncology Reviews

SN - 1970-5557

IS - 1

ER -